Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Yopi is an innovative, wearable technology that is both a personal trainer and a V...
Yopi is an innovative, wearable technology that...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Join the National Investor Network and get the latest information with your interests in mind.